Omrix to Begin Trial With Fibrin Patch

The FDA has cleared a Phase II trial of Omrix Biopharmaceuticals’ fibrin patch to treat mild to moderate bleeding.

The company said it anticipates beginning the trial in the second quarter of the year.

Last November, Omrix submitted an IND to start a study for mild, moderate and severe bleeding. The FDA has not approved the study, and the company is continuing discussions with the agency regarding the parameters of the study for severe bleeding.